Fulcrum Therapeutics, Inc. Sustainability Profile
Fulcrum Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for genetically defined diseases. Founded in 2016, Fulcrum has made significant strides in the industry, particularly in the field of rare genetic disorders. The company is renowned for its unique approach to drug development, leveraging its proprietary gene modulation platform to create targeted treatments. Fulcrum's lead product candidates aim to address unmet medical needs, setting the company apart in a competitive market. With a commitment to advancing science and improving patient outcomes, Fulcrum Therapeutics has established itself as a key player in the biopharmaceutical landscape, continually striving for excellence in the pursuit of transformative therapies.
DitchCarbon Score
How does Fulcrum Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fulcrum Therapeutics, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fulcrum Therapeutics, Inc.'s reported carbon emissions
Fulcrum Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Fulcrum Therapeutics may still be in the early stages of developing its climate commitments or reporting frameworks. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. However, without specific emissions data or targets, it is challenging to assess Fulcrum Therapeutics' position relative to its peers in terms of climate action. As the industry evolves, it is anticipated that Fulcrum Therapeutics will establish clearer commitments and reporting practices to align with global climate goals.
How Carbon Intensive is Fulcrum Therapeutics, Inc.'s Industry?
How Carbon Intensive is Fulcrum Therapeutics, Inc.'s Location?
Fulcrum Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fulcrum Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
